Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
DraftKings Inc. stock logo
DKNG
DraftKings
$25.15
-1.9%
$25.00
$20.46
$48.78
$12.73B1.6613.55 million shs14.78 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$61.00
+2.8%
$50.93
$22.28
$67.74
$23.55B1.056.95 million shs6.81 million shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
DraftKings Inc. stock logo
DKNG
DraftKings
-1.95%-11.79%+0.12%+17.41%-39.34%
Moderna, Inc. stock logo
MRNA
Moderna
+2.78%+10.11%+30.12%+13.93%+137.63%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
DraftKings Inc. stock logo
DKNG
DraftKings
$25.15
-1.9%
$25.00
$20.46
$48.78
$12.73B1.6613.55 million shs14.78 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$61.00
+2.8%
$50.93
$22.28
$67.74
$23.55B1.056.95 million shs6.81 million shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
DraftKings Inc. stock logo
DKNG
DraftKings
-1.95%-11.79%+0.12%+17.41%-39.34%
Moderna, Inc. stock logo
MRNA
Moderna
+2.78%+10.11%+30.12%+13.93%+137.63%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
DraftKings Inc. stock logo
DKNG
DraftKings
2.73
Moderate Buy$34.2136.01% Upside
Moderna, Inc. stock logo
MRNA
Moderna
1.83
Reduce$36.60-40.00% Downside

Current Analyst Ratings Breakdown

Latest MRNA and DKNG Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/22/2026
DraftKings Inc. stock logo
DKNG
DraftKings
Reiterated RatingBuy
6/22/2026
DraftKings Inc. stock logo
DKNG
DraftKings
Reiterated RatingMarket Outperform
6/22/2026
DraftKings Inc. stock logo
DKNG
DraftKings
Reiterated RatingMarket Outperform$34.00
6/18/2026
Moderna, Inc. stock logo
MRNA
Moderna
Reiterated RatingHold
6/12/2026
Moderna, Inc. stock logo
MRNA
Moderna
Reiterated RatingSell (D-)
6/11/2026
DraftKings Inc. stock logo
DKNG
DraftKings
Reiterated RatingOutperform
6/10/2026
DraftKings Inc. stock logo
DKNG
DraftKings
Reiterated RatingBuy
6/8/2026
DraftKings Inc. stock logo
DKNG
DraftKings
Reiterated RatingBuy$30.00
6/8/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetUnderperform$32.00 ➝ $34.00
6/5/2026
DraftKings Inc. stock logo
DKNG
DraftKings
Boost Price TargetBuy$43.00 ➝ $49.00
6/1/2026
DraftKings Inc. stock logo
DKNG
DraftKings
Set Price Target$29.00
(Data available from 6/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
DraftKings Inc. stock logo
DKNG
DraftKings
$6.05B2.06$0.73 per share34.58$1.27 per share19.80
Moderna, Inc. stock logo
MRNA
Moderna
$1.94B12.45N/AN/A$22.14 per share2.76
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
DraftKings Inc. stock logo
DKNG
DraftKings
$3.71M$0.06419.1720.45N/A0.93%13.51%2.24%8/5/2026 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$2.82B-$8.15N/AN/AN/A-143.55%-26.64%-19.32%7/31/2026 (Estimated)

Latest MRNA and DKNG Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2026Q1 2026
DraftKings Inc. stock logo
DKNG
DraftKings
$0.22$0.20-$0.02$0.03$1.63 billion$1.65 billion
5/1/2026Q1 2026
Moderna, Inc. stock logo
MRNA
Moderna
-$3.02-$3.40-$0.38-$3.40$236.37 million$389.00 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
DraftKings Inc. stock logo
DKNG
DraftKings
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
DraftKings Inc. stock logo
DKNG
DraftKings
3.03
1.02
1.02
Moderna, Inc. stock logo
MRNA
Moderna
0.08
2.41
2.35

Institutional Ownership

CompanyInstitutional Ownership
DraftKings Inc. stock logo
DKNG
DraftKings
37.70%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%

Insider Ownership

CompanyInsider Ownership
DraftKings Inc. stock logo
DKNG
DraftKings
47.18%
Moderna, Inc. stock logo
MRNA
Moderna
10.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
DraftKings Inc. stock logo
DKNG
DraftKings
5,500496.13 million262.06 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
4,700396.79 million353.93 millionOptionable

Recent News About These Companies

Barclays Sticks to Its Hold Rating for Moderna (MRNA)
Moderna (MRNA) Rises As Market Takes a Dip: Key Facts
Moderna snaps after six-session winning streak
FDA panel backs 1st mRNA flu vaccine
Should You Buy Moderna Before Aug. 5?
Moderna’s mRNA flu vaccine passes FDA AdCom, review underway
Moderna, Inc. $MRNA Shares Sold by Tobam
Promising Biotech Stocks To Follow Today - June 19th
FDA panel supports first mRNA-based flu vaccine

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
DraftKings stock logo

DraftKings NASDAQ:DKNG

$25.15 -0.50 (-1.95%)
Closing price 06/23/2026 04:00 PM Eastern
Extended Trading
$25.14 -0.01 (-0.06%)
As of 06/23/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

DraftKings Inc. operates as a digital sports entertainment and gaming company in the United States and internationally. It provides online sports betting and casino, daily fantasy sports, media, and other consumer products, as well as retails sportsbooks. The company also engages in the design and development of sports betting and casino gaming software for online and retail sportsbooks, and iGaming operators. In addition, it offers DraftKings marketplace, a digital collectibles ecosystem designed for mainstream accessibility that offers curated NFT drops and supports secondary-market transactions. The company is headquartered in Boston, Massachusetts.

Moderna stock logo

Moderna NASDAQ:MRNA

$61.00 +1.65 (+2.78%)
Closing price 06/23/2026 04:00 PM Eastern
Extended Trading
$60.98 -0.02 (-0.04%)
As of 06/23/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.